Synthetic Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 1, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share […]
Synthetic Biologics Announces Reverse Stock Split Read More »